Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

2.900 +0.050 (+1.75%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 09, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

June 05, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Present at Jefferies Healthcare Conference

June 02, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Looking Into Seres Therapeutics's Return On Capital Employed ↗

May 24, 2023

Via Benzinga

Preview: Seres Therapeutics's Earnings ↗

May 08, 2023

Via Benzinga

Where Seres Therapeutics Stands With Analysts ↗

April 28, 2023

Via Benzinga

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

May 30, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 09, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Why Seres Therapeutics Shares Are Surging Thursday Morning ↗

April 27, 2023

Via Benzinga

Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon ↗

April 20, 2023

These two biotech stocks might be significantly undervalued.

Via The Motley Fool

Where Seres Therapeutics Stands With Analysts ↗

March 08, 2023

Via Benzinga

Seres Therapeutics Earnings Preview ↗

March 06, 2023

Via Benzinga

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

May 09, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

May 08, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023

May 05, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday ↗

April 28, 2023

Wells Fargo raised the price target for Molina Healthcare, Inc. (NYSE: MOH) from $282 to $290. Wells Fargo analyst Stephen Baxter maintained an Underweight rating. Molina Healthcare shares gained 7.8%...

Via Benzinga

Snap, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

April 28, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Seres Therapeutics Announces $250 Million Debt Financing with Oaktree

April 27, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Tesla, Meta Platforms, Seres Therapeutics, Atomera, Roku: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

April 26, 2023

Via Benzinga

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

April 26, 2023

From Seres Therapeutics, Inc. and Nestlé Health Science

Via Business Wire

Amazon, Microsoft, Alphabet And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

April 26, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023 ↗

April 21, 2023

Via Benzinga

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 17, 2023

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

Via Benzinga

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 07, 2023

From Seres Therapeutics, Inc.

Via Business Wire

2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street ↗

April 04, 2023

Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.

Via The Motley Fool

Stocks React To February Jobs Report: The Winners And Losers ↗

March 10, 2023

The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors.

Via Benzinga

Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

March 09, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 07, 2023

From Seres Therapeutics, Inc.

Via Business Wire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 03, 2023

From Seres Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.